Genentech's rheumatoid arthritis biologic gains FDA approval

01/10/2010 | San Francisco Chronicle

The FDA approved Genentech's Actemra, the only rheumatoid arthritis drug that targets the interleukin-6 protein, which plays a role in joint inflammation. The treatment is expected to benefit patients who do not respond to Remicade, Humira or Enbrel, which target an inflammatory protein called tumor necrosis factor-alpha.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations